[1] DIDKOWSKA J, WOJCIECHOWSKA U, MANCZUK M, et al. Lung cancer epidemiology: contemporary and future challenges worldwide[J]. Ann Transl Med, 2016, 4(8): 150. [2] LAVIANO A, DI LAZZARO L, KOVERECH A. Nutrition support and clinical outcome in advanced cancer patients[J]. Proc Nutr Soc, 2018, 77(4): 388-393. [3] JIN F, HAN A, SHI F, et al. The postoperative neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after the complete resection of stage I non-small cell lung cancer[J]. Onco Targets Ther, 2016, 9: 6529-6537. [4] SCHREIBER R D, OLD L J, SMYTH M J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011,331(6024): 1565-1570. [5] BREMNES R M, BUSUND L T, KILVAER T L, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer[J]. J Thorac Oncol, 2016, 11(6): 789-800. [6] BARANYAI Z, JOSA V, TOTH A, et al. Paraneoplastic thrombocytosis in gastrointestinal cancer[J]. Platelets, 2016,27(4): 269-275. [7] KAWAI K, KITAYAMA J, TSUNO N H, et al. Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer[J]. Int J Colorectal Dis, 2013, 28(4): 527-535. [8] JURASZ P, ALONSO-ESCOLANO D, RADOMSKI M W. Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation[J]. Br J Pharmacol, 2004, 143(7): 819-826. [9] BELCHER D A, LUCAS A, CABRALES P, et al. Polymerized human hemoglobin facilitated modulation of tumor oxygenation is dependent on tumor oxygenation status and oxygen affinity of the hemoglobin-based oxygen carrier[J]. Sci Rep, 2020, 10(1): 11372. [10] 马军, 王杰军, 张力, 等. 肿瘤相关性贫血临床实践指南(2015-2016版)[J]. 中国实用内科杂志, 2016,36(S1): 1-21. [11] WEISS G, GOODNOUGH L T. Anemia of chronic disease[J]. N Engl J Med, 2005, 352(10): 1011-1023. [12] GUO M, SUN T, ZHAO Z, et al. Preoperative platelet to albumin ratio predicts outcome of patients with non-small-cell lung cancer[J]. Ann Thorac Cardiovasc Surg, 2021,27(2): 84-90. [13] KOMIYA K, NAKAMURA T, NAKASHIMA C, et al. SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer[J]. Onco Targets Ther, 2016,9: 6663-6668. [14] CONG L, HU L. The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma[J]. Int Immunopharmacol, 2017, 46: 75-79. [15] JIANG H, LI H, LI A, et al. Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer[J]. Oncotarget, 2016, 7(44): 72076-72083. [16] CHEN X L, XUE L, WANG W, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study[J]. Oncotarget, 2015,6(38): 41370-41382. [17] PENG D, ZHANG C J, GONG Y Q, et al. Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy[J]. Sci Rep, 2018, 8(1): 794. [18] PENG D, ZHANG C J, TANG Q, et al. Prognostic significance of the combination of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients with renal cell carcinoma after nephrectomy[J]. BMC Urol, 2018, 18(1): 20. |